In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease

Disease caused by nontuberculous mycobacteria (NTM) is increasing in frequency. The outcome of treatment for NTM lung disease is poor, particularly lung disease caused by Mycobacterium simiae and M. abscessus. Exploring synergy between active available drugs is a sensible way forward given the lack...

Full description

Bibliographic Details

Published in:	Antimicrobial agents and chemotherapy Vol. 56; no. 12; p. 6324
Main Authors:	van Ingen, Jakko, Totten, Sarah E, Helstrom, Niels K, Heifets, Leonid B, Boeree, Martin J, Daley, Charles L
Format:	Journal Article
Language:	English
Published:	United States 01.12.2012
Subjects:	Amikacin - pharmacology Amikacin - therapeutic use Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Clofazimine - pharmacology Clofazimine - therapeutic use Drug Synergism Microbial Sensitivity Tests Mycobacterium - drug effects Mycobacterium - growth & development Mycobacterium Infections - drug therapy Mycobacterium Infections - microbiology Nontuberculous Mycobacteria - drug effects Nontuberculous Mycobacteria - growth & development
ISSN:	1098-6596, 1098-6596
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!